Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics

Delayed Treatment of Papillary Thyroid Carcinoma Arising from Struma Ovarii in a Patient with History of Bilateral Salpingo-Oophorectomy: A Case Report

(2011) Alissa Collins et al.   Endocrine Practice

Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments

(2011) George Bartzokis   Frontiers in Bioscience-Landmark

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices

(2011) A. J. Mitchell et al.   PSYCHOLOGICAL MEDICINE

Sterol regulatory element binding protein and dietary lipid regulation of fatty acid synthesis in the mammary epithelium

(2010) Michael C. Rudolph et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs

(2010) Elaine H. Morrato et al.   ARCHIVES OF GENERAL PSYCHIATRY

Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia

(2010) Nagahide Takahashi et al.   PROGRESS IN NEUROBIOLOGY

Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients

(2010) Christoph Correll   PSYCHIATRIC SERVICES

Antipsychotic drugs and obesity

(2010) Christoph U. Correll et al.   TRENDS IN MOLECULAR MEDICINE

Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes

(2009) E. H. Morrato et al.   DIABETES CARE

Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol

(2009) I Kristiana et al.   PHARMACOGENOMICS JOURNAL

Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples

(2008) S Le Hellard et al.   MOLECULAR PSYCHIATRY

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

(2008) Jonathan M. Meyer et al.   SCHIZOPHRENIA RESEARCH

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

(2008) Jonathan M. Meyer et al.   SCHIZOPHRENIA RESEARCH